Provided by Tiger Fintech (Singapore) Pte. Ltd.

Global Partners LP

54.71
+0.88001.63%
Post-market: 54.710.00000.00%18:27 EDT
Volume:77.17K
Turnover:4.17M
Market Cap:1.84B
PE:23.10
High:54.71
Open:53.20
Low:52.76
Close:53.83
Loading ...

ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI

TipRanks
·
23 Jan

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?

Motley Fool
·
23 Jan

MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges

Zacks
·
22 Jan

GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise

Zacks
·
22 Jan

ImmunoPrecise Antibodies Says New Class of GLP-1 Therapies Developed Using AI; Shares Jump

MT Newswires Live
·
22 Jan

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Business Wire
·
22 Jan

Health Care Up on GLP-1 Alzheimer's Data -- Health Care Roundup

Dow Jones
·
22 Jan

Novo Nordisk's GLP-1 Drugs: Health Breakthroughs, Big Buybacks, and Medicare's Price-Cut Threat

GuruFocus.com
·
22 Jan

GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings

GuruFocus
·
21 Jan

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

GlobeNewswire
·
16 Jan

As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well -- Barrons.com

Dow Jones
·
15 Jan

Lexaria’s human GLP-1 study 5 receives IRB approval

TIPRANKS
·
15 Jan

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

ACCESSWIRE
·
15 Jan

DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly Growing Multi Billion Dollar Market

Business Wire
·
15 Jan

Stoneweg European REIT updates green financing framework

Jovi Ho
·
15 Jan

Lexaria Bioscience announces partial results from GLP-1-H24-3 study

TIPRANKS
·
14 Jan